Passions

Alpine skiing

Backpacking

San Francisco 49ers

Reading

Experience

Cerberus Ventures Leads Syntis Bio’s $38 Million Financing

July 1, 2025

Cooley advised Cerberus Ventures, a venture fund established in 2023 to invest in early-stage companies in sectors important to government and innovators, as lead investor in Syntis Bio’s $38 million financing. Partners Matthew Bartus, Marc Recht and Christophe Beauduin led the Cooley team advising Cerberus Ventures.

Related contacts

Matthew Bartus
Partner, San Francisco
Marc Recht
Partner, Boston
Christophe Beauduin
Partner, New York
Andrew Leonard
Associate, Washington, DC
Alex Abelson
Associate, New York
Dr. Marcelo Pomeranz
Associate, San Diego
Michael Fernando
Associate, London

Related Practices & Industries

Core Scientific Announces $625 Million Convertible Senior Notes

December 5, 2024

Cooley advised Core Scientific (NASDAQ: CORZ), a leader in digital infrastructure for bitcoin mining and high-performance computing, on its $625 million aggregate principal of 0.00% convertible senior notes due 2031, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of notes.

Read more

Related contacts

Daniel Peale
Partner, Washington, DC
Mischi a Marca
Partner, San Francisco
Eric Blanchard
Partner, Boston
Jason Savich
Partner, San Francisco
Peter Byrne
Partner, New York
Timothy Nguyen
Special Counsel, San Francisco
Sarah Curry
Associate, New York
Trey Reilly
Associate, New York
Matt Kong
Associate, San Francisco
Jayne M. Munger
Associate, New York
Margaret Barreto
Associate, San Francisco
Andrew Leonard
Associate, Washington, DC
Eileen Marshall
Partner, Washington, DC
Timothy Shapiro
Partner, Palo Alto
Francis Wheeler
Senior Counsel, Colorado

Related Practices & Industries

Lexeo Therapeutics Announces $100 Million IPO

November 3, 2023

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Read more

Related contacts

Eric Blanchard
Partner, Boston
Peter Byrne
Partner, New York
Div Gupta
Partner, New York
Xander Lee
Partner, Santa Monica
Barbara Mirza
Partner, Santa Monica
Aaron Pomeroy
Partner, Colorado
Phil Mitchell
Partner, New York
Mark Ballantyne
Partner, Reston
Francis Wheeler
Senior Counsel, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Stephanie Parker Palmer
Special Counsel, Reston
Joseph Lockinger
Special Counsel, New York
Christophe Beauduin
Partner, New York
Randy Sabett
Special Counsel, Washington, DC
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Carly Robinson
Associate, Reston
Calvin Lee
Associate, New York
Jayne M. Munger
Associate, New York
Megan Drill
Associate, San Diego
Erika Freeman
Associate, New York
Wyatt Kernell
Associate, Colorado
Wyatt Kernell
Associate, Colorado
Alexander Fullman
Associate, New York
Jason Minio
Paralegal Specialist, Boston
Andrew Leonard
Associate, Washington, DC

Related Practices & Industries

MapLight Therapeutics Closes Oversubscribed $225 Million Series C

November 3, 2023

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.

Read more

Related contacts

Christian Plaza
Partner, Reston
Matthew Schwee
Partner, Reston
David Brinton
Associate, Washington, DC
Dr. Michael Tuscan
Partner, Washington, DC
Jim Fulton
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Dr. Jason Valentine
Associate, Washington, DC
Cortney Smith
Senior Paralegal, Reston
Jeffery Wyzykowski
Patent Agent, Washington, DC
Dou Yeon Youn
Patent Agent, New York
Zhipeng Zheng
Patent Agent, Washington, DC
Andrew Leonard
Associate, Washington, DC

Related Practices & Industries

Admissions and credentials

District of Columbia

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.